Erlotinib/gemcitabine

Erlotinib/gemcitabine Reactions 1680, p131 - 2 Dec 2017 Interstitial lung disease: 2 case reports In the POLARIS (Post-Launch All-patient- Registration Surveillance) study for safety investigation of gemcitabine and erlotinib, 2 patients were described [ages and sexes not stated], who developed interstitial lung disease (ILD) following treatment with gemcitabine [route not stated] and erlotinib [duration of treatment to reactions onsets not stated] for pancreatic cancer. Case 1: The patient, who had pancreatic cancer, started receiving treatment with gemcitabine 1000 mg/m weekly for 3 weeks, followed by a 1-week rest and oral erlotinib 100mg once daily. However, following gemcitabine and erlotinib administration, the patient developed ILD, which was considered to be treatment related. Eventually, the ILD had recovered, but the patient experienced a sequela. Case 2: The patient, who had pancreatic cancer, started receiving treatment with gemcitabine 1000 mg/m2 weekly for 3 weeks, followed by a 1-week rest and oral erlotinib 100mg once daily. However, following gemcitabine and erlotinib administration, the patient developed ILD, which was considered to be treatment related [outcome not stated]. Author comment: "Outcomes of ILD events were . . . 1 patient (1.9%) had a sequela and the outcome was unknown for 1 patient (1.9%)." "After reviewing the POLARIS data, the ILD review committee recommended that patients with pancreatic cancer should be evaluated for the risk factors identified here prior to beginning GE treatment. During GE treatment. . .If ILD symptoms occur, discontinuation of GE is recommended." Furuse J, et al. Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis. Japanese Journal of Clinical Oncology 47: 832-839, No. 9, 24 May 2017. Available from: URL: http:// doi.org/10.1093/jjco/hyx075 - Japan 803284325 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Erlotinib/gemcitabine

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/erlotinib-gemcitabine-40jeFYiqsl
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39062-5
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p131 - 2 Dec 2017 Interstitial lung disease: 2 case reports In the POLARIS (Post-Launch All-patient- Registration Surveillance) study for safety investigation of gemcitabine and erlotinib, 2 patients were described [ages and sexes not stated], who developed interstitial lung disease (ILD) following treatment with gemcitabine [route not stated] and erlotinib [duration of treatment to reactions onsets not stated] for pancreatic cancer. Case 1: The patient, who had pancreatic cancer, started receiving treatment with gemcitabine 1000 mg/m weekly for 3 weeks, followed by a 1-week rest and oral erlotinib 100mg once daily. However, following gemcitabine and erlotinib administration, the patient developed ILD, which was considered to be treatment related. Eventually, the ILD had recovered, but the patient experienced a sequela. Case 2: The patient, who had pancreatic cancer, started receiving treatment with gemcitabine 1000 mg/m2 weekly for 3 weeks, followed by a 1-week rest and oral erlotinib 100mg once daily. However, following gemcitabine and erlotinib administration, the patient developed ILD, which was considered to be treatment related [outcome not stated]. Author comment: "Outcomes of ILD events were . . . 1 patient (1.9%) had a sequela and the outcome was unknown for 1 patient (1.9%)." "After reviewing the POLARIS data, the ILD review committee recommended that patients with pancreatic cancer should be evaluated for the risk factors identified here prior to beginning GE treatment. During GE treatment. . .If ILD symptoms occur, discontinuation of GE is recommended." Furuse J, et al. Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis. Japanese Journal of Clinical Oncology 47: 832-839, No. 9, 24 May 2017. Available from: URL: http:// doi.org/10.1093/jjco/hyx075 - Japan 803284325 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off